Phaseline

Targets › SFTPA1

SFTPA1 (Pulmonary surfactant-associated protein A1): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 4; Neurology; next expected readout Jul 2028.

In presence of calcium ions, it binds to surfactant phospholipids and contributes to lower the surface tension at the air-liquid interface in the alveoli of the mammalian lung and is essential for normal respiration. Enhances the expression of MYO18A/SP-R210 on alveolar macrophages (By similarity)..; FUNCTION: (Microbial infection) Recognition of M.tuberculosis by dendritic cells may occur partially via this…. (UniProt, Q8IWL2)

Open in Phaseline: the race on SFTPA1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Medical University of GrazPoractant alfa (Curosurf®)
Pulmonary surfactant replacement therapy
SFTPB, SFTPC, SFTPA1, SFTPA2Phase 4Neonates and Preterm InfantsJul 2028

Conditions

Neonates and Preterm Infants (1)

Modalities

small molecule (1)

Companies

Medical University of Graz (1)

Related targets

SFTPB (1) SFTPC (1) SFTPA2 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.